Cooper Companies, Inc.
Most Recent
JNJ’s Vision Care Segment Witnessed Solid Growth in Q1 2018
In June, the FDA approved Johnson & Johnson’s iDESIGN Refractive Studio, which can be utilized for customized LASIK treatment.
How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017
In 4Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.56 billion compared to $1.44 billion in 4Q16, which reflected ~8% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
Analysts’ Recommendations for Haemonetics and Peers in March 2018
In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.
Inside Johnson & Johnson’s Vision Care Performance in 3Q17
In 3Q17, JNJ vision care generated revenues of $1.1 billion, which reflected a ~48% YoY (year-over-year) rise and a 3% QoQ (quarter-over-quarter) rise.
Novartis Expects to Restore Alcon’s Profitability in the Future
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
Will Novartis’s Alcon Business See Growth in 2017?
Novartis (NVS) expects its Alcon business to report low-single-digit revenue growth in 2017.
Stellar YTD 2016 for MFS Massachusetts Investors Growth Stock Fund
The MFS Massachusetts Investors Growth Stock Fund – Class A (MIGFX) is the only fund in this review that has outperformed the passively managed SPDR S&P 500 ETF Trust (SPY).
Cooper Companies Shows Strong Relative Earnings Compared to Peers
The PowerShares DWA Healthcare Momentum Portfolio (PTH) invests 4.54% of its holdings in Cooper.
Cooper Companies Reported Mixed 2Q15 Results
Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.
Lone Pine Adds New Stake in The Cooper Companies
Cooper’s results for fiscal 1Q15 beat the EPS estimates, but it missed on revenue. Cooper’s revenue grew 10% year-over-year to $445.2 million.
Lone Pine Capital Holdings Traded During 4Q14
Tiger cub Stephen Mandel’s Lone Pine Capital’s US long portfolio saw a slight fall from $25.5 billion in 3Q14 to $23.8 billion in 4Q14.
